These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 9707769

  • 1. [Conservative treatment of locally advanced bladder carcinoma: neoadjuvant chemotherapy, TUR and radiotherapy. Results in 40 patients].
    Serretta V, Vasile P, Falletta V, Piazza F, Pavone C, Pavone-Macaluso M.
    Arch Ital Urol Androl; 1998 Jun; 70(3 Suppl):37-40. PubMed ID: 9707769
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A, Pinar B, Arellano R, López M, Marín A, Jiménez U, Pérez Torrubia A.
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W.
    J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug 14; 354(9178):533-40. PubMed ID: 10470696
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N.
    J Urol; 1996 Jun 14; 155(6):1897-902. PubMed ID: 8618282
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F.
    Cancer; 2004 Dec 01; 101(11):2540-8. PubMed ID: 15481058
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):665-72. PubMed ID: 14529770
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
    Startsev VY.
    Arch Ital Urol Androl; 2002 Jun 01; 74(2):54-6. PubMed ID: 12161935
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Invasive bladder cancer: a single-institution experience with bladder-sparing approach.
    Zapatero A, Martín de Vidales C, Marín A, Cerezo L, Arellano R, Rabadán M, Pérez-Torrubia A.
    Int J Cancer; 2000 Oct 20; 90(5):287-94. PubMed ID: 11091353
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.